Despite improved revenue growth forecasts and a lower future P/E ratio reflecting better earnings expectations, analysts have significantly reduced the fair value for Adaptimmune Therapeutics, as indicated by the consensus price target dropping from $1.67 to $0.96.
What's in the News
- Adaptimmune settled litigation with MD Anderson regarding a breach of contract under a 2016 alliance, agreeing to a financial settlement the company deems immaterial to its financial position or results.
- The company’s listing was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market following non-compliance with the minimum $1.00 bid price rule, granting Adaptimmune an additional 180 days to regain compliance and avoid potential delisting.
Valuation Changes
Summary of Valuation Changes for Adaptimmune Therapeutics
- The Consensus Analyst Price Target has significantly fallen from $1.67 to $0.96.
- The Consensus Revenue Growth forecasts for Adaptimmune Therapeutics has significantly risen from -10.3% per annum to -5.3% per annum.
- The Future P/E for Adaptimmune Therapeutics has significantly fallen from 28.64x to 20.67x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.